Form 4: Protagonist Therapeutics Executive Suneel Gupta Reports Tax-Related Stock Transaction
SEC Form 4 Filing
Suneel Gupta, Chief Development Officer of Protagonist Therapeutics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On February 26, 2024, Suneel Gupta, the Chief Development Officer of Protagonist Therapeutics, Inc. (PTGX), had 4,282 shares of common stock withheld by the issuer to satisfy tax obligations.
- This withholding was related to the vesting of 12,000 restricted stock units.
- Following the transaction, Gupta directly owns 183,285 shares of Protagonist Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a neutral event related to tax obligations on vested stock, not indicative of positive or negative sentiment regarding the company's performance.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates a standard tax withholding procedure related to equity compensation.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of stock transaction (tax withholding) and vesting of restricted stock units. |
| 02/28/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.